NRx Pharmaceuticals (NASDAQ:NRXPW – Get Free Report) is expected to be releasing its resultson Tuesday, May 19th. Analysts expect NRx Pharmaceuticals to post earnings of $0.2887 per share and revenue of $25.5670 million for the quarter.
NRx Pharmaceuticals Stock Down 16.7%
NASDAQ:NRXPW opened at $0.01 on Tuesday. The stock has a 50-day simple moving average of $0.02 and a 200-day simple moving average of $0.05. NRx Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.18.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small?molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.
Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls.
Featured Articles
- Five stocks we like better than NRx Pharmaceuticals
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
